Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks: Top 5 Stocks

4. GSK (NYSE:GSK)

Number of Hedge Fund Holdings in Q4 2024: 38

Number of Hedge Fund Holdings in Q4 2025: 43

Performance Since Cramer’s Remarks: 38.9%

Date/Month of Cramer’s Remarks: March 25th, 2025

Pharma giant GSK (NYSE:GSK) made a move to enter the weight loss market earlier this year after it announced that it would acquire 35Pharma and bolster its portfolio to include the HS235 drug that can be used for fat-selective weight loss and muscle mass preservation. Its shares are up by 38% over the past year and by a similar percentage since Cramer discussed the firm in March 2025. GSK (NYSE:GSK) ‘s stock closed 7.3% higher on February 4th, 2026, after the firm reported its fourth quarter earnings report. The results saw the firm post 8.6 billion pounds in revenue and 25.5 pence in earnings to beat analyst estimates. On October 29th, 2025, GSK (NYSE:GSK) ‘s shares closed 5% higher after the firm’s third-quarter earnings saw it raise its 2025 revenue growth estimates to a 6% to 7% from an earlier 3% to 5%. It posted 8.6 billion pounds in revenue and 55 pence on earnings per share to also beat estimates. Here is what Cramer said about the firm a year back:

“Not at all, not at all. I like GSK very much. I think it’s a very good company. I think Dame Walmsley’s doing a terrific job. I think the stock, the fact that it’s at a very low PE and it yields 4%, that’s my kind of stock. I think you put it away, buy it, and put it away.”